Previous studies have shown that uliginosin B inhibits dopamine reuptake in rat brain. This compound occurs in Hypericum polyanthemum and H. caprifoliatum for which was reported to have antinociceptive effect sensitive to naloxone. The aim of this study was to assess the antinociceptive effect of uliginosin B and to evaluate the involvement of opioid and dopaminergic receptors activation. Uliginosin B presented antinociceptive effect in hot-plate and abdominal writhing tests, in mice, at doses that did not impair the motor coordination (15 mg/kg, i.p.). Uliginosin B in high dose (90 mg/kg, i.p.) presented ataxic effect in the rotarod apparatus. These effects seem to be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone and sulpiride, but it was unaffected by SCH 23390. On the other hand, the motor impairment induced by uliginosin B was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. However, the receptors' activation appears to be indirect since uliginosin B did not bind to opioid and dopaminergic receptors. Thus, uliginosin B effects probably are due to its ability to inhibit monoamine reuptake with consequent activation of dopamine receptors and indirect stimulation of opioid system.
Introduction
Phloroglucinol derivatives are molecules present in several plant species, e.g. Hypericum perforatum, Humulus lupulus and some species of Elaphoglossum genus. This group of substances displays biological activities such as antimicrobial (Jayasuriya et al., 1991; Rocha et al., 1995; Saddiqe et al., 2010) , anxiolytic (Zanoli et al., 2005) , antidepressant (Linde et al., 2008; Viana et al., 2005) and antinociceptive (Abdel-Salam, 2005; Galeotti et al., 2010) . Clinical trials showed that phloroglucinols reduce pain in irritable bowel (Cargill et al., 1992; Chassany et al., 2007; Ducrotte et al., 2005; Jafri et al., 2006) and burning mouth syndromes (Sardella et al., 2008) .
Hyperforin is one of the most known phloroglucinol derivative; it occurs in H. perforatum, a European species with clinical antidepressant effect (Linde et al., 2008) . Hyperforin inhibits monoamines (Muller et al., 2001) , glutamate and GABA (gamma-aminobutyric acid) reuptake (Wonnemann et al., 2000) with similar efficacy (Gobbi et al., 2001; Müller, 2003) without interacting directly with their neuronal transporters (Singer et al., 1999) ; changes membrane fluidity (Eckert et al., 2004) ; influences cell functions by blocking calcium (Fisunov et al., 2000) , sodium and potassium ions voltage-gated channels (Chatterjee et al., 1999) . This compound also acts on ligand-gated channels, such as TRPC6 (canonical transient receptor potential 6) (Tu et al., 2010) and NMDA (N-methyl-D-aspartic acid) receptors (Kumar et al., 2006) . Recently, authors have demonstrated that hyperforin presents thermal antinociception mediated by opioid system (Galeotti et al., 2010) .
Research carried out by our group has shown that uliginosin B (Fig. 1) , a phloroglucinol derivative from Hypericum species native to Rio Grande do Sul, Brazil, such as H. caprifoliatum (Nor et al., 2008) , H. myrianthum (Ferraz et al., 2002 ), H. polyanthemum and H. carinatum (Nor et al., 2004) , inhibits monoamines synaptosomal reuptake in rat brain, especially dopamine without binding to its neuronal carriers (Stein et al., 2012) . This compound presents a dimeric structure consisting of filicinic acid and phloroglucinol moieties (Ferraz et al., 2002;  Progress in Neuro-Psychopharmacology & Biological Psychiatry 39 (2012) [80] [81] [82] [83] [84] [85] [86] [87] Abbreviations:
13 C RMN, carbon nuclear magnetic resonance; 1 H RMN, proton nuclear magnetic resonance; ANOVA, analysis of variance; CGEN, Conselho de Gestão do Patrimônio Genético; CIOMS, Council for International Organization of Medical Sciences International; COD, codeine; DAMGO, [D-Ala2, N-MePhe4, Gly-ol]-o enkephalin; DTT, dithiothreitol; FEPPS, Fundação Estadual de Produção e Pesquisa em Saúde; GABA, gamma-aminobutyric acid; GDP, guanosine diphosphate; GTPγS, Guanosine-5′-O-(3-thio) triphosphate; HAL, haloperidol; HPLC, high performance liquid chromatography; i.p., intraperitoneal route; IBAMA, Instituto Brasileiro do Meio Ambiente; MOR, morphine; NAL, naloxone; NMDA, N-methyl-D-aspartic acid; p.o., per os; RM, repeated measures; SCH 23390, R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol; SCH, SCH-23390; SEM, standard error of the mean; SULP, sulpiride; TRPC6, canonical transient receptor potential 6; ULI, uliginosin B. Leal et al., 2010) . This molecular feature has been proposed as chemotaxonomic marker for species of Hypericum native to South Brazil (Nor et al., 2004) and differs from hyperforin and ad-hyperforin, which possess a bicyclononane skeleton substituted with several isoprene chains.
Other compounds isolated from South Brazilian Hypericum species presented biological activities linked to dopaminergic and opioid modulation: the benzopyran HP1 (6-isobutyryl-5,7-dimethoxy-2,2-dimethyl-benzopyran) exhibited antinociceptive effect that was blocked by naloxone (Haas et al., 2010) ; the flavonoid hyperoside demonstrated antidepressant-like activity in rodents that seems to be underlain by dopaminergic neurotransmission (Haas et al., 2011) .
In this study we have assessed uliginosin B antinociceptive effect on hot-plate and writhing tests in mice. The possible involvement of opioid system and dopaminergic neurotransmission was also investigated by evaluating the influence of antagonists (naloxone, SCH 23390 and sulpiride) on the antinociceptive effect of uliginosin B in the hot-plate and rotarod tests as well as by using binding assays to dopaminergic and opioid receptors. 
Materials and methods

Plant material
Uliginosin B extraction and isolation procedures
Dried and powdered aerial parts of H. myrianthum were extracted with n-hexane by maceration (3× 24 h at 20°C). The combined extracts were evaporated to dryness under reduced pressure and submitted to silica gel column chromatography G 60 (Merck®) (50 cm× 3 cm) using n-hexane:dichloromethane gradient system as the mobile phase. The uliginosin B enriched fraction obtained was purified by preparative TLC performed on 20 cm× 20 cm glass-supported plates covered with 0.5 mm layers of silica gel GF 254 (Merck®), with n-hexane: dichloromethane (1:1 v/v) as chromatographic eluent. Band was detected using UV light (254 nm) and the purity of uliginosin B was confirmed by high performance liquid chromatography (HPLC) analysis (Nunes et al., 2009 ). The uliginosin B retention time was compared with standard compound (authentic sample), previously identified by 1 H and 13 C RMN (Rocha et al., 1995 (Rocha et al., , 1996 .
Drugs and treatments
GDP (guanosine diphosphate), GTPγS (guanosine-5′-O-(3-thio) triphosphate), SCH 23390 (R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol) and haloperidol by Sigma- Uliginosin B was suspended in saline with an additional 2% polysorbate 80 immediately before using. Considering that drugs absorption rate is dependent on the anatomical site from which absorption takes place, uliginosin B was administered by oral (gavage) or intraperitoneal route 60 and 30 min before behavioral testing, respectively. The doses were chosen based on previous results published by our group (Stein et al., 2012) . All treatments were administered at 10 mL/kg body weight.
Behavioral experiments
Animals
Adult male CF1 mice (25-35 g) purchased from Fundação Estadual de Produção e Pesquisa em Saúde (FEPPS-RS, Brazil) colony were used. The animals were housed 8 mice per plastic cages (L: 28 cm, W: 17 cm, H: 13 cm) under a 12 h light/dark cycle (lights on at 7:00 h) at constant temperature (23 ± 1°C) with free access to standard certified rodent diet (Nuvilab CR-1®) and tap water. All experiments were approved by a local research ethical committee (UFRGS, number 2008195) and were in compliance with Brazilian law (Brasil, 2008) and Council for International Organization of Medical Sciences International (CIOMS) guiding principles for biomedical research involving animals (Bankowski and Howard-Jones, 1985) .
Writhing induced by acetic acid
This test was carried out according to Haas et al. (2010) and Viana et al. (2003) . The animals were treated with uliginosin B (15 and 90 mg/kg, p.o.), dipyrone (150 mg/kg p.o.) or vehicle (10 mL/kg p.o.) 60 min before receiving an intraperitoneal acetic acid injection (0.8%, 10 mL/kg). Immediately after, mice were then individually placed in glass observation chambers and observed during 15 min in which the number of abdominal writhing was counted. The percentage of antinociceptive activity was calculated as follows:
N represents the average number of writhing of the control group and N′ the average number of abdominal writhing of the test group.
Hot-plate test
Firstly, mice were habituated to the nonfunctioning hot-plate apparatus (Ugo Basile) for 1 min. Thirty minutes later the animals were placed on the functioning hot-plate (55 ± 2°C) to determine baseline responsiveness. The time elapsed until the animal licked one of its hind paws or jumped was recorded in seconds (latency time). Mice that presented a baseline reaction of more than 20 s were not used. Subsequently, the animals received uliginosin B (15 and 90 mg/kg p.o. or 5, 10, 15 and 90 mg/kg, i.p.), morphine (10 mg/kg, p.o or 4 mg/kg, i.p.) and vehicle (10 mL/kg, p.o. or i.p.). To assess the involvement of opioid system and dopaminergic neurotransmission, animals were treated with naloxone (non-selective opioid receptor antagonist, 2.5 mg/kg, s. 
Motor coordination test: rotarod
Briefly, the apparatus consisted of a cylinder of 3 cm of diameter rotating at 5 rpm. One day before testing, the animals were trained once during 5 min. On the test day, the mice were place in the apparatus again to determine the baseline responsiveness. Only mice that were able to stay 90 s balanced on the rotarod were selected for testing. The selected mice received uliginosin B (90 mg/kg, p.o. or 15 and 90 mg/kg, i.p.), vehicle (10 mL/kg, p.o. or i.p.). Codeine + acetaminophen (10 + 166 mg/kg, p.o. or i.p.) were used as an antinociceptive control and haloperidol (4 mg/kg, p.o. or i.p.) was used as an internal standard. In another set of experiments mice were treated with naloxone (2.5 mg/kg, s.c.), sulpiride (10 mg/kg, i.p.) or SCH 23390 (15 μg/kg, i.p.) 10, 15 or 30 min, respectively, before receiving uliginosin B (90 mg/kg, i.p.) or vehicle (10 mL/kg, i.p.). The pretreatment was given immediately after the baseline responsiveness evaluation. Mice performance was measured 30 min -i.p. or 60 min -p.o. after the drug administration. The integrity of motor coordination was assessed on the basis of the longest time of permanence and the number of falls in a 5 min period.
2.5. In vitro assays 2.5.1. Animals
Male Sprague-Dawley rats, weighing 180-200 g, were purchased from IFFA-CREDO/Charles River Laboratories (Domaine des Oncins, Saint-Germain sur L'Arbresle, France). They were housed by four in Makrolon cages (L: 40 cm, W: 25 cm, H: 18 cm), with free access to water and food (U.A.R., France) and kept in a well ventilated room, at a temperature of 21 ± 1°C, under a 12 h light/dark cycle (lights on between 7:00 h). The procedures used in this study are in compliance with the European Communities Council Directive number 609 (Directive, 1986).
Membrane preparations
Crude membrane preparations were isolated according to the modified method described elsewhere (Viana et al., 2005) . Nontreated rats were sacrificed by decapitation. Striatum (brain region enriched in D 1 and D 2 receptors), thalamus (brain region enriched in opioid receptors) and forebrain were removed and homogenized in 20 vol. of 0.32 M sucrose. The homogenates were centrifuged (1 g for 15 min); the supernatants from two centrifugations were combined and centrifuged (17 g for 30 min). The resulting pellet was then suspended in Tris buffer (pH 7.4) contained 50 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl 2 , and 1 mM EDTA for GTPγS binding; 50 mM Tris/HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , and 1 mM MgCl 2 for dopaminergic receptor binding; 50 mM Tris/HCl, 300 mM NaCl, and 5 mM KCl for opioid receptor binding, sonicated and centrifuged (50 g for 10 min). The final protein concentration was determined by the method of Lowry (Lowry et al., 1977) . These membranes were freshly used for receptor bindings or GTPγS binding.
Receptor binding assays
In M). The final volume was 500 μL. Nonspecific binding was determined in presence of naloxone 10 μM (opioid receptors), SCH 23390 30 μM (D 1 -like receptors) or sulpiride 300 μM (D 2 -like receptors). Incubations were stopped by dilution with 3 mL of ice-cold incubation medium and immediate filtration through GF/B filters, previously soaked, for at least 1 h, in 0.5% polyethyleneimine. Each tube and filter was rinsed twice with 3 mL of ice-cold incubation medium. Filters were counted for radioactivity by liquid scintillation spectrometry in 4 mL of Ultima Gold. Four independent experiments for each assay were carried out in duplicate. -10 − 10 M uliginosin B, in a total volume of 1 mL. Basal binding was assessed in the absence of opioid peptide analogue and presence of GDP. The non-specific binding was assessed in the presence of 10 μM GTPγS. The entire mixture was incubated at 25°C for 2 h and filtered through Whatman GF/B glass fiber filters, which had been pre-soaked for 2 h in Tris buffer, and washed three times with 4 mL of ice-cold Tris buffer. Bound radioactivity was determined in Tri-Carb 2100TR liquid scintillation counter after overnight extraction of the filters in 4 mL of Ultima Gold scintillation fluid. Four independent experiments for each assay were carried out in duplicate. 
Statistical analysis
The data were evaluated using one or two-way RM analysis of variance -ANOVA -followed by Student-Newman-Keuls test depending on the experimental design. All results were expressed in mean± S.E.M. The analyses were performed using Sigma Stat 3.2 software, Jandel Scientific Corporation. Differences were considered statistically significant at p b 0.05.
Results
Antinociceptive effect of uliginosin B by oral and intraperitoneal route
The effects of the oral administration of uliginosin B 15 and 90 mg/kg on the abdominal writhing induced by acetic acid are presented in Table 1 . Both doses of uliginosin B inhibited abdominal writhing in more than 90% in comparison with vehicle group [one-way ANOVA F (3,23) = 93.152; p b 0.001], this effect was comparable to dipyrone 150 mg/kg effect (86% inhibition). In addition, the latencies of mice that received uliginosin B 15 (pb 0.01) and 90 mg/kg (pb 0.05) were significantly higher than the latency of the group treated with uliginosin B 10 mg/kg, characterizing a dose-response relationship.
The effect of uliginosin B on motor performance was evaluated in the rotarod apparatus (Fig. 3) . The oral administration of uliginosin B 90 mg/kg did not alter the rotarod performance (Fig. 3A and B) . (Fig. 3D ) of mice at the second exposition to rotarod. Uliginosin B 15 mg/kg (i.p.) did not alter motor performance on rotarod test. Considering these results, the intraperitoneal treatment with uliginosin B was selected to be used for investigating antinociceptive and ataxic mechanism action.
Effect of opioid and dopaminergic systems on uliginosin B thermal antinociception and motor effect
The possible involvement of opioid and dopaminergic systems in the uliginosin B effect was evaluated on hot-plate and rotarod tests by using naloxone, SCH 23390 and sulpiride prior to the intraperitoneal administration of uliginosin B. Naloxone, SCH 23390 and sulpiride themselves (Fig. 4A) . The pretreatment of mice with SCH 23390 (15 μg/kg, i.p.) was not able to prevent the uliginosin B antinociceptive effect in hot-plate test (Fig. 4B) . Two-way RM ANOVA revealed a significant effect of treatment [F (5,119 Fig . 5 shows the effect of the antagonist pretreatments on the ataxic effect of uliginosin B 90 mg/kg (i.p.) in the rotarod test. The pretreatment with naloxone (2.5 mg/kg, s.c.) abolished the motor impairment induced by uliginosin B (Fig. 5A and B) . Two-way RM ANOVA analysis revealed that uliginosin B increased the number of falls [F treatment 
Discussion
The results from our study clearly demonstrate that uliginosin B presents antinociceptive effect in mice when evaluated in acetic acid induced writhing and hot-plate tests. The uliginosin B effect on thermal nociception was dose-dependent and the maximal effect was reached at doses that did not impair motor coordination (15 mg/kg, i.p.; 90 mg/kg, p.o.) . Thus, it is reasonable to assume that this dimeric phloroglucinol contributes to the H. caprifoliatum and H. polyanthemum antinociceptive effects previously reported by Haas et al. (2010) and Viana et al. (2003) .
Besides the antinociceptive effect, uliginosin B at the highest dose (90 mg/kg, i.p.) presented an ataxic effect in the rotarod. Plummer et al. (1991) support the validity of hot-plate test as antinociceptive assay even in the presence of a substantial impairment of motor performance. However, the rotarod impairment also could be indicative of neurotoxicity, hypotension, muscle relaxation, sedation or catalepsy (Le Bars et al., 2001) . Some of these effects, such as hypotension and sedation, could be at least in part consequence of dopaminergic or opioid system activation (Lahlou, 1998; Pelissier et al., 2006; Spetea et al., 2010) .
The antinociceptive and ataxic effects seem to be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone (uliginosin B 15 mg/kg, i.p.) and sulpiride (uliginosin B 15 mg/kg, i.p. and 90 mg/kg, i.p.) but it was unaffected by SCH 23390. On the other hand, the impairment induced by uliginosin B 90 mg/kg, i.p. on the mice rotarod performance was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. Therefore, it is possible that the D 1 -like receptors are implicated in the ataxic effects but do not account to the antinociceptive effect whereas opioid and D 2 -like receptors activation appears to underlie both effects. However, receptors activation seems to be indirect in any case, given that we demonstrated that uliginosin B up to 10 The uliginosin B action on the dopaminergic neurotransmission is in agreement with the dopaminergic activity of H. caprifoliatum and its main phloroglucinol derivative described by Viana et al. (2005 Viana et al. ( , 2006 . Moreover, recently Stein et al. (2012) demonstrated that uliginosin B inhibits monoamines synaptosomal reuptake in rat brain, especially dopamine. Thus, probably the compound stimulates the dopaminergic neurotransmission by increasing dopamine levels in synaptic cleft with consequent activation of dopamine receptors. A similar pharmacological profile was also demonstrated for hyperforin, which presents non-specific pre-synaptic effects resulting from non-selective inhibition of the uptake of several neurotransmitters and indirect interaction with dopamine and opioid receptors (Mennini and Gobbi, 2004) . The antidepressant-like activity of hyperforin was completely antagonized by BD 1047 -selective σ 1 antagonist (Cervo et al., 2005) . Furthermore, hyperforin inhibits rat bladder contractility in vitro, at least in part, by opioid receptors activation (Capasso et al., 2004) .
The antinociceptive mechanism of action of antidepressant compounds has been matter of discussion (Densmore et al., 2010; Ripoll et al., 2006; Yasuda et al., 2005) . The antinociceptive effect of serotonin/ noradrenaline reuptake inhibitors enhanced when they were combined with dopamine reuptake inhibitors (Pedersen et al., 2005) or direct D 2 receptor agonist -quinpirole (Munro, 2007) . Gray et al. (1998) showed that opioid antagonists reduce the antinociceptive potency of several antidepressants and suggested that antidepressants may induce endogenous opioid peptide release. Millan (2002) and Wood (2008) demonstrated that the activation of dopaminergic neurotransmission, particularly through D 2 -like receptor, induces antinociceptive effects. Dopaminergic autoreceptor antagonists and agonists have been proposed to develop drugs for treating pain (Wood, 2008) . For instance, apomorphine -dopaminergic agonist -showed antinociceptive effect which is blockaded by central D 2 antagonists, but not by peripheral D 2 antagonists (Pelissier et al., 2006) ; amisulpiride and levosulpiride have antinociceptive effect by acting as an antagonist of D 2 /D 3 dopaminergic receptors, with selective preference for presynaptic autoreceptor (Weizman et al., 2003) .
It is known that the mesolimbic dopaminergic pathway activation stimulates the release of endogenous opioid peptides (Soderman and Unterwald, 2009 ) what could explain the opioid effect of uliginosin B. 
